Head of Strategic Alliances & Channel Partners
Lausanne, Switzerland - February 25, 2021 - Saphetor SA, a Switzerland-based precision medicine company using bioinformatics to apply human genome data to benefit people, announced today a distribution agreement with Annar Health Technologies S.A.S., a leading provider of technology, reagents and comprehensive innovative solutions tailored to the health sector in Colombia.
David Carreño, Genetics Unit Manager of Annar Health Technologies S.A.S., said: “We are delighted with this new distribution agreement, with Varsome our clients find a complete solution for bioinformatic analysis of human genomics data.”
Tomas Kucera, Head of Business Development at Saphetor SA, commented: ‘We are excited to collaborate with Annar Diagnostica Import S.A.S. as regional distributor in Colombia for our VarSome products and services, and we are ready to work closely with their team and clients.’
About Annar Health Technologies S.A.S.
Annar Health Technologies S.A.S. a reagent and medical device provider that offers custom-made solutions to our customers, such as: consulting service to improve the operation efficiency, Lab software, point of care, quality control, blood bank, among others and data analysis modules, Business Intelligence, to a complete process of just in time delivery, with the most complete value proposition in the market based on innovation and flexibility. We generate an impact on health in a profitable and sustainable way.
About Saphetor SA
VarSome is the emerging global standard platform for human genome data. Varsome.com is the world's largest community and knowledge base for human genome variant data, and VarSome's Premium, Clinical and API tools enable anyone and any organization, from individual healthcare professionals to hospitals and pharmaceutical companies, to harness and apply the power of this community and data to improve health and lives worldwide. VarSome is created by Saphetor, a Switzerland-based precision medicine company using bioinformatics to apply human genome data to benefit people.
Submit a Comment